Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-12
2011-12-20
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S250000, C548S255000, C548S262200, C548S311100, C548S364100, C514S383000, C514S385000, C514S397000
Reexamination Certificate
active
08080571
ABSTRACT:
There is provided compounds of formula I,wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4and R5have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
REFERENCES:
patent: 5312820 (1994-05-01), Ashton et al.
patent: 5424450 (1995-06-01), Boswell et al.
patent: 5444067 (1995-08-01), Kivlighn et al.
patent: 5512681 (1996-04-01), Boswell et al.
patent: 5545651 (1996-08-01), Duncia et al.
patent: 6335451 (2002-01-01), Kleemann et al.
patent: 40 23 215 (1992-01-01), None
patent: 0 399 731 (1990-11-01), None
patent: 0 399 732 (1990-11-01), None
patent: 0 499 415 (1992-08-01), None
patent: WO 93/04045 (1993-03-01), None
patent: WO 93/04046 (1993-03-01), None
patent: WO 94/11379 (1994-05-01), None
patent: WO 94/28896 (1994-12-01), None
patent: WO 99/43339 (1999-09-01), None
patent: WO 02/096883 (2002-12-01), None
patent: WO -02/096883 (2002-12-01), None
patent: WO 03/064414 (2003-08-01), None
patent: WO 2004/046128 (2004-06-01), None
patent: WO 2004/046137 (2004-06-01), None
patent: WO 2004/046141 (2004-06-01), None
patent: WO 2004/085420 (2004-10-01), None
Cramer, R.D., et al; “Prospective Identification of Biologically Active Structures by Topomer Shape Similarity Searching”;J. Med. Chem.; vol. 42; pp. 3919-3933 (1999).
Murugesan, N., et al; “Biphenylsulfonamide Endothelin Antagonists: Structure-Activity Relationships of a Series of Mono- and Disubstituted Analogues and Pharmacology of the Orally Active Endothelin Antagonist 2′-Amino-N-(3,4-dimethyl-5-isoxazolyl)-4′-(2-methylpropyl)[1,1′-biphenyl]-2-sulfonamide (BMS-187308)”;J Med. Chem., vol. 41; pp. 5198-5218 (1998).
Smith, D.A., et al; “Pharmacokinetics and metabolism in Drug Design”;Wiley-VCH; pp. 3/7-4/7 (2001).
Wingstrand, J.; “An introduction to Medicinal Chemistry and Drug Discovery”;Lund University; pp. 5/7-7/7 (2005).
International Preliminary Report on Patentability; Int'l Appln. No. PCT/GB2006/001319; Int'l Filing Date Apr. 12, 2006 (6 pgs).
Ardaillou, R.; “Angiotensin II Receptors”;J. Am. Soc. Nephrol., 10: pp. 530-539 (1999).
De Gasparo, M., et al; “International Union of Pharmacology. XXIII. The Angiotensin II Receptors”;Pharmacol Rev.; 52, pp. 415-472 (2000).
Pandya, T., et al; “3-D QSAR Studies of Triazolinone Based Balanced AT1/AT2Receptor Antagonists”;Bioorganic&Medicinal Chemistry; 9, pp. 291-300 (2001).
Alterman Mathias
Hallberg Anders
Wu Xiongyu
Coppins Janet L
McKane Joseph K.
Nixon & Vanderhye
Vicore Pharma AB
LandOfFree
Tricyclic angiotensin II agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic angiotensin II agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic angiotensin II agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4316029